الإحصائيات الأساسية
| CIK | 1374339 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ProMIS Neurosciences, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 4, 2025 |
Calculation of Filing Fee Tables S-3 ProMIS Neurosciences Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward I |
|
| September 4, 2025 |
As filed with the Securities and Exchange Commission on September 4, 2025. Table of Contents As filed with the Securities and Exchange Commission on September 4, 2025. |
|
| September 3, 2025 |
Exhibit 99.1 ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310 Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2025 |
AT THE MARKET OFFERING AGREEMENT August 13, 2025 Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT August 13, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: ProMIS Neurosciences Inc., a corporation continued under the Business Corporations Act (Ontario) (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1.Definitions. The terms that fol |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 13, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employ |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025. Table of Contents As filed with the Securities and Exchange Commission on August 13, 2025. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 13, 2025 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT August 13, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: ProMIS Neurosciences Inc., a corporation continued under the Business Corporations Act (Ontario) (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1.Definitions. The terms that fol |
|
| August 13, 2025 |
Calculation of Filing Fee Tables S-3 ProMIS Neurosciences Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward I |
|
| August 13, 2025 |
Exhibit 4.3 INDENTURE Dated as of , 20 Between ProMIS Neurosciences Inc. as Issuer And [ ], as Trustee Debt Securities TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 3 SECTION 1.03 Incorporation by Reference of Trust Indenture Act 3 SECTION 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 4 SECTION 2.0 |
|
| August 13, 2025 |
Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Positi |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (C |
|
| August 13, 2025 |
Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 ProMIS Neurosciences Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2015 Stock Plan Common Shares, no par value per share Other 2,136,409 $ 0.57 $ 1,217,753.13 0.0001531 $ 186 |
|
| August 13, 2025 |
Exhibit 10.1 PROMIS NEUROSCIENCES INC. 2025 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of ProMIS Neurosciences Inc. (the “Company”) and its |
|
| July 28, 2025 |
Exhibit 99.1 ProMIS Neurosciences Announces Private Placement Financing $3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 28, 2025 – ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and develo |
|
| July 28, 2025 |
Form of PIPE Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 28, 2025, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the entities listed on Exhibit A attached to this Agreement (the “Investors”). WHEREAS, the Company and the Investors are executing and del |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| July 28, 2025 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 28, 2025, is entered into by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitt |
|
| July 28, 2025 |
Exhibit 4.1 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 22, 2025 |
PROMIS NEUROSCIENCES INC. Pre-Funded Warrants to Purchase 984,736 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-274658 PROSPECTUS SUPPLEMENT (To Prospectus dated September 29, 2023) PROMIS NEUROSCIENCES INC. Pre-Funded Warrants to Purchase 984,736 Common Shares We are offering pre-funded warrants to purchase 984,736 common shares in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement and |
|
| July 22, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 22, 2025, is entered into by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitt |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| July 22, 2025 |
Exhibit 99.2 ProMIS Neurosciences Announces Private Placement Financing $2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 22, 2025 – ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company c |
|
| July 22, 2025 |
Exhibit 4.1 Warrant Certificate No. Issuance Date: [ ] PROMIS NEUROSCIENCES INC. PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), for value received on [ ] (the “Issuance Date”), hereby issues to [ ] (the “Holder”) this Pre-Funded Warrant (the “Warrant”) to purchase [ ] Common Shares (a |
|
| July 22, 2025 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| July 22, 2025 |
Exhibit 99.1 ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the- Market Under Nasdaq Rules CAMBRIDGE, Massachusetts., July 22, 2025 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s |
|
| July 22, 2025 |
Form of PIPE Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 22, 2025, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the entities listed on Exhibit A attached to this Agreement (the “Investor”). WHEREAS, the Company and the Investor are executing and deliv |
|
| July 22, 2025 |
Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 22, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 22, 2025, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). Recitals A.The |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Comm |
|
| June 13, 2025 |
ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan Exhibit 10.1 PROMIS NEUROSCIENCES INC. 2025 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ProMIS Neurosciences Inc. 2025 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of ProMIS Neurosciences Inc. (the “Company”) and its |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 12, 2025 |
Exhibit 10.3 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] VIA HAND DELIVERY February 19, 2025 Gavin Malenfant [***] Dear Gavin: In connec |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Comm |
|
| May 12, 2025 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] December 2, 2024 UBC File: F16-05805 / 2025-1413 VIA EMAIL Neil K. Warma Presid |
|
| May 12, 2025 |
Exhibit 99.1 ProMIS Neurosciences Announces First Quarter 2025 Financial Results First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts – May 12, 2025 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generatio |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ☐ De |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 31, 2025 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the capital stock of ProMIS Neurosciences Inc. (the "Company") is intended as a summary only and therefore is not a complete description of the Company’s capital stock. This description is based upon, and is qualified by reference to, the Articles of the Company, as amended (the "Arti |
|
| March 31, 2025 |
Exhibit 10.47 ProMIS Neurosciences (US) Inc. Larry Alstiel 31 Water Street, Stonington CT, 06378 BY EMAIL March 1, 2025 Employment Offer Dear Larry: On behalf of ProMIS Neurosciences (US), Inc. (the “Company”), I am pleased to offer you employment as Chief Medical Officer (“CMO”). The new terms of your employment are set forth below in this Employment Offer (the “Employment Agreement”). 1.Position |
|
| March 31, 2025 |
PROMIS NEUROSCIENCES INC. Up to $10,354,794 Common Shares Table of Contents PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To prospectus supplement dated January 5, 2024 To Prospectus dated September 29, 2023) Registration No. |
|
| March 31, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction ProMIS Neurosciences (US), Inc. Delaware |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41429 PROMIS N |
|
| March 31, 2025 |
Exhibit 99.1 ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts – March 31, 2025 – ProMIS |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Co |
|
| March 31, 2025 |
Insider trading policy adopted March 27, 2025 Exhibit 19.1 PROMIS NEUROSCIENCES INC. Insider Trading POLICY ProMIS Neurosciences Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences ass |
|
| February 25, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2025 |
Exhibit 99.1 ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026 CAMBRIDGE, Massachusetts – February 25, 2025 – ProMIS |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) |
|
| January 27, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) ( |
|
| January 27, 2025 |
Exhibit 99.1 NASDAQ: PMN Targeting the underlying cause of neurodegenerative diseases Copyright 2025, ProMIS Neurosciences, Inc. | Non Confidential Legal Disclaimers This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different |
|
| January 10, 2025 |
Exhibit 99.1 ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients CAMBRIDGE, Massachusetts – January 10, 2025 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing prec |
|
| January 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (C |
|
| November 14, 2024 |
PMN / ProMIS Neurosciences, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-pmn093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PROMIS NEUROSCIENCES INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 74346M406 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 14, 2024 |
PMN / ProMIS Neurosciences, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer’s disease On track to initiate Phase 1b clinical tr |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) |
|
| November 6, 2024 |
PMN / ProMIS Neurosciences, Inc. / Sclar Jeremy M. - SC 13G/A Passive Investment SC 13G/A 1 tm2427185d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M406 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) C |
|
| November 6, 2024 |
EX-99.1 2 tm2427185d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including the amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neuros |
|
| November 5, 2024 |
PMN / ProMIS Neurosciences, Inc. / GORDON MICHAEL S - SC 13G/A Passive Investment SC 13G/A 1 tm2427185d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M406 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) C |
|
| November 5, 2024 |
EX-99.1 2 tm2427185d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including the amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neuros |
|
| October 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) ( |
|
| October 16, 2024 |
PMN / ProMIS Neurosciences, Inc. / Shaf QIC LLC - SC 13G Passive Investment SC 13G 1 tm2426305d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* PROMIS NEUROSCIENCES INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 74346M406 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| October 16, 2024 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| October 10, 2024 |
Employment Agreement with Neil Warma, dated October 8, 2024 Exhibit 10.1 ProMIS Neurosciences (US), Inc. October 8, 2024 BY EMAIL Neil Warma Re:Employment Offer Dear Neil: On behalf of ProMIS Neurosciences (US), Inc. (the “Company”), I am pleased to offer you the position of the Company’s Chief Executive Officer (“CEO”). The new terms of your employment are set forth below. This Employment Offer letter (the “Employment Agreement”) shall supersede the offer |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (C |
|
| October 10, 2024 |
Form of Indemnification Agreement Exhibit 10.2 INDEMNIFICATION AGREEMENT BETWEEN: (the “Indemnitee”) AND: PROMIS NEURSCIENCES, INC., a company incorporated under the laws of Canada and having its head office at 1920 Yonge Street, Suite 200, Toronto, Ontario M4S 3E2 (the “Company”) WHEREAS: A.The Indemnitee is, was or proposes to become, a member of the Board of Directors (the “Board”) and/or a senior officer of the Company and in |
|
| September 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ☐ De |
|
| September 4, 2024 |
VIA EDGAR September 4, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024. Table of Contents As filed with the Securities and Exchange Commission on August 29, 2024. |
|
| August 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ProMIS Neurosciences, Inc. |
|
| August 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| August 8, 2024 |
Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease that met objectives for tolerability, safety and pharmacokinetics Secured up to $122.7 million in private placement financing from leading healthcare specialty funds to adv |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Co |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 5, 2024 |
PMN / ProMIS Neurosciences, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G 1 greatpoint-pmn072624.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ProMIS Neurosciences Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 74346M406 (CUSIP Number) July 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| July 26, 2024 |
Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 26, 2024 |
ProMIS Neurosciences Reports Promising Top-Line Data from its Phase 1a Alzheimer's Trial Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 26, 2024 – ProMIS Neurosciences, Inc. |
|
| July 26, 2024 |
Exhibit 99.1 ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing $30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 for Alzheimer’s Disease patients Proceeds expected to support Company beyond 6 month and |
|
| July 26, 2024 |
Form of Unit Purchase Agreement Exhibit 10.1 PROMIS NEUROSCIENCES INC. UNIT PURCHASE AGREEMENT Table of Contents Page 1. Purchase and Sale of Units. 1 1.1 Sale and Issuance of Units 2 1.2 Closing; Delivery. 2 1.3 Use of Proceeds 3 1.4 Defined Terms Used in this Agreement 3 2. Representations and Warranties of the Company 7 2.1 Organization, Good Standing, Corporate Power and Qualification 7 2.2 Capitalization. 7 2.3 Subsidiary |
|
| July 26, 2024 |
Exhibit 4.4 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 26, 2024 |
Exhibit 4.3 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 26, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of July 26, 2024 (the “Effective Date”) between ProMIS Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (Ontario) (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “Purchaser” and colle |
|
| July 26, 2024 |
Exhibit 4.1 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| July 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Comm |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| May 14, 2024 |
Exhibit 99.1 ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario – May 14, 2024 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Comm |
|
| April 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission |
|
| April 30, 2024 |
Exhibit 99.1 ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE, Massachusetts and TORONTO, Ontario – April 30, 2024 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of a |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ☐ De |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14 (a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 1, 2024 |
PROMIS NEUROSCIENCES INC. Up to $13,580,895 Common Shares Table of Contents PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To prospectus supplement dated January 5, 2024 To Prospectus dated September 29, 2023) Registration No. |
|
| April 1, 2024 |
Exhibit 99.1 ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights Top-line Data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario – April 1, 2024 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation an |
|
| April 1, 2024 |
ProMIS Neurosciences Inc. Clawback Policy. Exhibit 97.1 PROMIS NEUROSCIENCES INC. COMPENSATION RECOVERY POLICY Adopted as of November 28, 2023 ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover |
|
| April 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Com |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41429 PROMIS N |
|
| April 1, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction ProMIS Neurosciences (US), Inc. Delaware |
|
| February 5, 2024 |
DE:23J0 / ProMIS Neurosciences, Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No.1)* ProMIS Neurosciences Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 74346M406 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| January 5, 2024 |
PROMIS NEUROSCIENCES INC. Up to $25,000,000 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-274658 PROSPECTUS SUPPLEMENT (To Prospectus dated September 29, 2023) PROMIS NEUROSCIENCES INC. Up to $25,000,000 Common Shares We have entered into an At The Market Offering Agreement, or the sales agreement, with BTIG, LLC, or BTIG, dated January 5, 2024, relating to the sale of our common shares, no par value, having an agg |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 5, 2024 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employ |
|
| January 5, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT January 5, 2024 BTIG, LLC 65 East 55th St. New York, New York 10022 Ladies and Gentlemen: ProMIS Neurosciences Inc., a corporation continued under the Business Corporations Act (Ontario) (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (the “Manager”) as follows: 1.Definitions. The terms that follow, when used in this Agreement |
|
| January 3, 2024 |
Exhibit 10.1 PROMIS NEUROSCIENCES (US), INC. December 30, 2023 Neil Warma Dear Neil, On behalf of ProMIS Neurosciences (US), Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer. You will be employed to serve as the Interim Chief Executive Officer (“Interim |
|
| January 3, 2024 |
ProMIS Neurosciences, Inc. Announces Leadership Transition Exhibit 99.1 ProMIS Neurosciences, Inc. Announces Leadership Transition Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer CAMBRIDGE, Massachusetts and TORONTO, Ontario, January 3, 2024 - ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) |
|
| January 2, 2024 |
PMN / ProMIS Neurosciences, Inc. / Sclar Jeremy M. - SC 13G/A Passive Investment SC 13G/A 1 tm2333203d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 7436M117 (CUSIP Number) December 26, 2023 (Date of Event which Requires Filing of this Statement) Che |
|
| January 2, 2024 |
EX-99.1 2 tm2333203d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including the amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neuros |
|
| December 27, 2023 |
PMN / ProMIS Neurosciences, Inc. / GORDON MICHAEL S - SC 13G/A Passive Investment SC 13G/A 1 tm2333079d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M117 (CUSIP Number) December 25, 2023 (Date of Event which Requires Filing of this Statement) Ch |
|
| December 27, 2023 |
EX-99.1 2 tm2333079d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including the amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neuros |
|
| December 8, 2023 |
Exhibit 10.1 FINAL SHARE EXCHANGE AGREEMENT This SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of December 4, 2023, is made and entered into by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and each of the shareholders listed on Schedule A hereto (each, a “Holder” and collectively, the “Holders”). RECITALS WHE |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 (December 4, 2023) PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction |
|
| December 8, 2023 |
Exhibit 3.1 Ministry of Public and Business Service Delivery Ministère des Services au public et aux entreprises Certificate of Amendment Certificat de modification Business Corporations Act Loi sur les sociétés par actions PROMIS NEUROSCIENCES INC. Corporation Name / Dénomination sociale 1678696 Ontario Corporation Number / Numéro de société de l’Ontario This is to certify that these articles are |
|
| November 20, 2023 |
Exhibit 99.1 ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study TORONTO, Ontario and CAMBRIDGE, Massachusetts – November 20, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the |
|
| November 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) |
|
| November 14, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases Dosing of first subjects in first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheim |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) |
|
| September 27, 2023 |
VIA EDGAR September 27, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 27, 2023 |
VIA EDGAR September 27, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 27, 2023 |
As filed with the Securities and Exchange Commission on September 27, 2023. As filed with the Securities and Exchange Commission on September 27, 2023. Registration No. 333- 274656 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 98-0647155 (State or Other Jurisdiction of |
|
| September 27, 2023 |
Exhibit 4.3 INDENTURE Dated as of , 20 Between ProMIS Neurosciences Inc. as Issuer And [], as Trustee Debt Securities TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 3 SECTION 1.03 Incorporation by Reference of Trust Indenture Act 3 SECTION 1.04 Rules of Construction 4 ARTICLE II THE SECURITIES 4 SECTION 2.01 |
|
| September 27, 2023 |
As filed with the Securities and Exchange Commission on September 27, 2023. As filed with the Securities and Exchange Commission on September 27, 2023. Registration No. 333- 274658 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 98-0647155 (State or Other Jurisdiction of |
|
| September 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ProMIS Neurosciences, Inc. |
|
| September 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ProMIS Neurosciences Inc. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023. Table of Contents As filed with the Securities and Exchange Commission on September 22, 2023. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023. Table of Contents As filed with the Securities and Exchange Commission on September 22, 2023. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023. Table of Contents As filed with the Securities and Exchange Commission on September 22, 2023. |
|
| September 5, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neurosciences Inc., a Canadian corporation. This Jo |
|
| September 5, 2023 |
DE:23J / ProMIS Neurosciences Inc. / GORDON MICHAEL S - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M117 (CUSIP Number) August 23, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| September 5, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neurosciences Inc., a Canadian corporation. This Jo |
|
| September 5, 2023 |
DE:23J / ProMIS Neurosciences Inc. / Sclar Jeremy M. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M117 (CUSIP Number) August 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| August 30, 2023 |
DE:23J / ProMIS Neurosciences Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* ProMIS Neurosciences Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 74346M406 (CUSIP Number) August 23, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| August 30, 2023 |
Joint Filing Agreement by and among the Reporting Persons Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of ProMIS Neurosciences Inc. |
|
| August 22, 2023 |
Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| August 22, 2023 |
Exhibit 4.1 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| August 22, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 12 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| August 22, 2023 |
Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (C |
|
| August 22, 2023 |
Exhibit 10.2 Execution Version Registration Rights Agreement This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of August 21, 2023 (the “Effective Date”) between ProMis Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (Ontario) (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “ |
|
| August 22, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces $20.4 Million Private Placement Financing At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts – August 21, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of anti |
|
| August 22, 2023 |
Exhibit 10.1 Execution Version PROMIS NEUROSCIENCES INC. UNIT PURCHASE AGREEMENT Table of Contents Page 1. Purchase and Sale of Units 1 1.1 Sale and Issuance of Units 1 1.2 Closing; Delivery 1 1.3 Use of Proceeds 3 1.4 Defined Terms Used in this Agreement 3 2. Representations and Warranties of the Company 5 2.1 Organization, Good Standing, Corporate Power and Qualification 5 2.2 Capitalization 6 2 |
|
| August 22, 2023 |
Form of Registration Rights Agreement Exhibit 10.2 Execution Version Registration Rights Agreement This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of August 21, 2023 (the “Effective Date”) between ProMis Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (Ontario) (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “ |
|
| August 22, 2023 |
Form of Unit Purchase Agreement Exhibit 10.1 Execution Version PROMIS NEUROSCIENCES INC. UNIT PURCHASE AGREEMENT Table of Contents Page 1. Purchase and Sale of Units 1 1.1 Sale and Issuance of Units 1 1.2 Closing; Delivery 1 1.3 Use of Proceeds 3 1.4 Defined Terms Used in this Agreement 3 2. Representations and Warranties of the Company 5 2.1 Organization, Good Standing, Corporate Power and Qualification 5 2.2 Capitalization 6 2 |
|
| August 22, 2023 |
Press Release dated August 21, 2023 Exhibit 99.1 ProMIS Neurosciences Announces $20.4 Million Private Placement Financing At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts – August 21, 2023 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of anti |
|
| August 22, 2023 |
Exhibit 4.1 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Ontario, Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (C |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 14, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 11 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| August 14, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights Presented compelling preclinical data supporting therapeutic potential of PMN310 to treat Alzheimer’s disease, and the promise of disease prevention with a computationally derived Alzheimer’s disease vaccine candidate at AAIC 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, August 14, 2023 (G |
|
| July 14, 2023 |
BCA - Articles of Continuance - PROMIS NEUROSCIENCES INC. - OCN:1678696 - July 13, 2023 Ministry of Public and Business Service Delivery Articles of Continuance Business Corporations Act 1.Corporation Name PROMIS NEUROSCIENCES INC. 2.Date of Incorporation/Amalgamation September 21, 2005 3.Name of jurisdiction the corporation is leaving Canada - Federal 4.The continuance was authorized by home juri |
|
| July 14, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 10 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| July 14, 2023 |
Exhibit 3.3 BY-LAW NO. 2 A BY-LAW RELATING TO THE NOMINATION OF DIRECTORS PROMIS NEUROSCIENCES INC. (THE “CORPORATION”) CONTENTS: 1.Interpretation 2. Nomination of Directors 3. Nominations of Directors by Nominating Shareholders 4. Eligibility Requirements for Nominated Candidates 5. Board Discretion LEGAL41335779.1 BY-LAW NO. 2 PROMIS NEUROSCIENCES INC. The Corporation is committed to: (i) facili |
|
| July 14, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAW NO. 1 OF PROMIS NUEROSCIENES INC. (as of July 13, 2023) 121731739v1 LEGAL41336753.1 TABLE OF CONTENTS Page 1.INTERPRETATION1 2.DIRECTORS1 3.MEETING OF DIRECTORS4 4.REMUNERATION OF DIRECTORS5 5.SUBMISSION OF CONTRACTS OR TRANSACTIONS TO SHAREHOLDERS FOR APPROVAL6 6.FOR THE PROTECTION OF DIRECTORS AND OFFICERS6 7.INDEMNITIES TO DIRECTORS AND OFFICERS6 8 |
|
| July 10, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 09 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| July 10, 2023 |
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange Exhibit 99.1 ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange ● Company to voluntarily delist from the Toronto Stock Exchange (TSX) ● Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeu |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| June 30, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 08 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| June 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 22, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 18, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 07 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 15, 2023 |
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights Exhibit 99.1 ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights ● Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s disease ● Presented preclinical data supporting target identification and candidate differentiation across pipeline of antibody therapeutics at international neurology co |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 06 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| May 8, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease • In preclinical studies, PMN310 demonstrated the ability to selectively target and protect against pathogenic Aβ oligomers • The IND clearance of PMN310 in the Alzheimer’s disease indication paves the way for initiation of clinical evaluation TORONTO, Ontario a |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 27, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 05 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41429 PRO |
|
| April 10, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 04 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| April 10, 2023 |
Press Release, dated April 10, 2023 Exhibit 99.1 ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 10, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases s |
|
| April 10, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310 TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 10, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases s |
|
| April 10, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 03 (this “Prospectus Supplement”) amends and supplements the Prospectus dated November 8, 2022 (the “Prospectus”) of ProMIS Ne |
|
| March 17, 2023 |
As filed with the Securities and Exchange Commission on March 17, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 17, 2023. |
|
| March 8, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction ProMIS Neurosciences (US), Inc. Delaware |
|
| March 8, 2023 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the capital stock of ProMIS Neurosciences Inc. (the “Company”) is intended as a summary only and therefore is not a complete description of the Company’s capital stock. This description is based upon, and is qualified by reference to, the Articles of the Company, as amended (the “Arti |
|
| March 8, 2023 |
Exhibit 99.1 ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights - Completed all preclinical studies and manufacturing to support PMN310 IND submission to U.S. Food and Drug Administration - Preclinical data that further characterize ongoing programs, including PMN310, to be presented in 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS N |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-41429 PROMIS N |
|
| March 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| February 3, 2023 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neurosciences Inc., a Canadian corporation. |
|
| February 3, 2023 |
CA:PMN / ProMIs Neorscience / Sclar Jeremy M. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M117 (CUSIP Number) October 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| December 6, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 02 (this ?Prospectus Supplement?) amends and supplements the Prospectus dated November 8, 2022 (the ?Prospectus?) of ProMIS Ne |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissi |
|
| November 16, 2022 |
ProMIS Neurosciences Inc. Annual Incentive Plan Exhibit 10.53 ProMIS Neurosciences Inc. Annual Incentive Plan 1. Purpose. The ProMIS Neurosciences Inc. Annual Incentive Plan (the ?Plan?) provides the framework for establishing annual cash incentive compensation awards for each fiscal year (a ?Plan Year,? currently the calendar year) of ProMIS Neurosciences Inc. (the ?Company?), beginning with the 2022 Plan Year. The primary purposes of the Plan |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2022 |
Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights - Closed US$7.4 million private placement - Appointed Gail Farfel, Ph.D., as Chief Executive Officer - Continued progress toward investigational new drug (IND) submission for PMN310 in Alzheimer?s disease TORONTO, Ontario and CAMBRIDGE, Massachusetts ? November 14, 2022 ? ProMIS Neurosciences Inc |
|
| November 14, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333- 268103 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2022) PROMIS NEUROSCIENCES INC. Up to 1,383,755 Common Shares Underlying Units Up to 345,939 Common Shares Underlying Warrants This Prospectus Supplement No. 01 (this ?Prospectus Supplement?) amends and supplements the Prospectus dated November 8, 2022 (the ?Prospectus?) of ProMIS N |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2022 |
[remainder of page left intentionally blank] VIA EDGAR November 8, 2022 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| November 8, 2022 |
As filed with the Securities and Exchange Commission on November 8, 2022. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2022. |
|
| November 4, 2022 |
As filed with the Securities and Exchange Commission on November 4, 2022. As filed with the Securities and Exchange Commission on November 4, 2022. Registration No. 333-268103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 2834 98-0647155 (State or Other Jurisdiction of Incorp |
|
| November 1, 2022 |
Exhibit 10.3.5 ? Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] ? January 11, 2022 UBC File: F16-05805 ? VIA EMAIL Dr. Elliot Goldstein Pre |
|
| November 1, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on November 1, 2022. |
|
| November 1, 2022 |
Exhibit 10.50 PROMIS NEUROSCIENCES INC. UNIT PURCHASE AGREEMENT TABLE OF CONTENTS Page 1. Purchase and Sale of 1 1.1 Sale and Issuance of 1 1.2 Closing; Delivery 1 1.3 Use of Proceeds 2 1.4 Defined Terms Used in this Agreement 3 2. Representations and Warranties of the Company 5 2.1 Organization, Good Standing, Corporate Power and Qualification 5 2.2 Capitalization 6 2.3 Subsidiar 6 2.4 Authorizat |
|
| November 1, 2022 |
? Exhibit 10.52 PROMIS NEUROSCIENCES 1920 YONGE ST. TORONTO, ONTARIO, M4S 3E2, CANADA January 21, 2022 Neil Cashman Dear Neil; On behalf of ProMIS Neurosciences., a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite 200, Toronto, Ontario, M4S 3E2 (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter |
|
| November 1, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) PROMIS NEUROSCIENCES INC. |
|
| November 1, 2022 |
Exhibit 10.51 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of October 11, 2022 (the “Effective Date”) between ProMis Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “Purchaser” and collectivel |
|
| November 1, 2022 |
ProMIS Neurosciences Inc. 2015 Stock Option Plan. EX-10.38 5 pmn-20220630xex10d38.htm EXHIBIT-10.38 Exhibit 10.38 PROMIS NEUROSCIENCES INC. STOCK OPTION PLAN - 2 - ARTICLE 1 PURPOSE AND INTERPRETATION Purpose 1.1The purpose of the Plan is to provide the Corporation with a equity-related mechanism to attract, retain and motivate Directors, Officers, Employees and Consultants and create incentives for such individuals to contribute toward the long |
|
| November 1, 2022 |
Exhibit 10.3.6 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] November 24, 2021 To UBC Finance re: Increase of ProMIS Neurosciences SRA wit |
|
| October 21, 2022 |
CA:PMN / ProMIs Neorscience / GORDON MICHAEL S - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ProMIS Neurosciences Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 74346M117 (CUSIP Number) October 11, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| October 21, 2022 |
EX-99.1 2 d266029dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any amendments thereto, the “13G”) with respect to the common shares, no par value per share, of ProMIS Neurosciences I |
|
| October 17, 2022 |
EX-4.2 4 tm2228219d1ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGIS |
|
| October 17, 2022 |
Form of Unit Purchase Agreement Exhibit 10.50 PROMIS NEUROSCIENCES INC. UNIT PURCHASE AGREEMENT TABLE OF CONTENTS Page 1. Purchase and Sale of 1 1.1 Sale and Issuance of 1 1.2 Closing; Delivery 1 1.3 Use of Proceeds 2 1.4 Defined Terms Used in this Agreement 3 2. Representations and Warranties of the Company 5 2.1 Organization, Good Standing, Corporate Power and Qualification 5 2.2 Capitalization 6 2.3 Subsidiar 6 2.4 Authorizat |
|
| October 17, 2022 |
Exhibit 4.3 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS |
|
| October 17, 2022 |
Exhibit 1.2 AMENDMENT NO. 1 TO AMENDED AND RESTATED PLACEMENT AGENT AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED PLACEMENT AGENT AGREEMENT, dated as of October 5, 2022 (this ?Amendment?), is by and between ProMIS Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (the ?Company?) and Ceros Financial Services, Inc., a Massachusetts corporation (the ?P |
|
| October 17, 2022 |
Form of Registration Rights Agreement Exhibit 10.51 Registration Rights Agreement This Registration Rights Agreement (this ?Agreement?) is made and entered into effective as of , 2022 (the ?Effective Date?) between ProMis Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (the ?Company?), and the persons who have executed the signature page(s) hereto (each, a ?Purchaser? and collectively, the ?Pu |
|
| October 17, 2022 |
Exhibit 1.1 AMENDED AND RESTATED PLACEMENT AGENT AGREEMENT September 22, 2022 Ceros Financial Services, Inc. 1445 Research Boulevard Rockville, MD 20850 Re: ProMIS Neurosciences Inc. Ladies and Gentlemen: This Amended and Restated Placement Agent Agreement (this ?Agreement?) is made by and between ProMIS Neurosciences Inc., a corporation incorporated under the Canada Business Corporations Act (the |
|
| October 17, 2022 |
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement EX-99.1 8 tm2228219d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement Toronto, Ontario and Cambridge, MA – October 12, 2022 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated in the development of |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commissio |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commiss |
|
| September 13, 2022 |
EX-99.1 4 tm2225652d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer New CEO brings 25 years’ experience and successful track record in neurological and neuropsychiatric drug development TORONTO, Ontario and CAMBRIDGE, Massachusetts – September 13, 2022– ProMIS Neurosciences, Inc. (Nasdaq: PMN) |
|
| September 13, 2022 |
Exhibit 10.48 PROMIS NEUROSCIENCES 1920 YONGE ST. TORONTO, ONTARIO, M4S 3E2, CANADA September 12, 2022 Mr. Eugene Williams Dear Gene, This agreement (the ?Strategic Services Agreement? or the ?Agreement?) is between you and ProMIS Neurosciences Inc., a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite 200, Toronto, Ontario, M4S 3E2 (the ?Compa |
|
| September 13, 2022 |
Exhibit 10.49 ProMIS Neurosciences 1920 Yonge St. Toronto, Ontario, M4S 3E2, Canada September 12, 2022 Gail Farfel Dear Gail, On behalf of ProMIS Neurosciences, a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite 200, Toronto, Ontario, M4S 3E2 (the ?Company?), I am pleased to offer you employment with the Company. The purpose of this letter is |
|
| September 7, 2022 |
Calculation of Filing Fee Tables. EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PROMIS NEUROSCIENCES INC. |
|
| September 7, 2022 |
As filed with the Securities and Exchange Commission on September 7, 2022 As filed with the Securities and Exchange Commission on September 7, 2022 Registration No. |
|
| August 15, 2022 |
ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results TORONTO, Ontario and CAMBRIDGE, Massachusetts ? August 15, 2022 ? ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (?ProMIS? or the ?Company?), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 29, 2022 |
Exhibit 16.1 July 28, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 USA Commissioners: We have read the statements made by ProMIS Neurosciences Inc. (copy attached), which we understand will be included under Item 4.01 of Form 8-K which will be filed with the Securities and Exchange Commission on July 29, 2022. We agree with the statements concerning our Firm conta |
|
| July 29, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction of incorporation) (Commission F |
|
| July 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2022 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-41429 98-0647155 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| July 8, 2022 |
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN” Exhibit 99.1 ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN” TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 8th, 2022 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the develo |
|
| July 6, 2022 |
ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto, Ontario M4S 3E2 July 6, 2022 CORRESP 1 filename1.htm ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto, Ontario M4S 3E2 July 6, 2022 BY EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Ms. Jeanne Baker, Mr. Jeffrey Gabor and Mr. Gary Newberry RE: ProMIS Neurosciences Inc. Registration Statement on Form 10-12B File No. 001-4142 |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 to FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 98-0647155 (State or other jurisdiction of incorporation or organization) (I.R.S. employer iden |
|
| July 1, 2022 |
Press Release of ProMIS Neurosciences, Inc. dated June 22, 2022. Exhibit 99.1 June 22, 2022 ProMIS Neurosciences Announces Debt Amendment and Conversion TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (?ProMIS? or the ?Company?), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implica |
|
| July 1, 2022 |
Troutman Pepper Hamilton Sanders LLP 401 9th Street, NW, Suite 1000 Washington, DC 20004 troutman. |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 to FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 98-0647155 (State or other jurisdiction of incorporation or organization) (I.R.S. employer iden |
|
| June 30, 2022 |
EX-3.1.3 2 tm229830d7ex3-1d3.htm EXHIBIT 3.1.3 Exhibit 3.1.3 Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les sociétés par actions ProMIS Neurosciences Inc. Corporate name / Dénomination sociale 432461-7 Corporation number / Numéro de société I HEREBY CERTIFY that the articles of the above-named corporation are amended under section 178 of |
|
| June 22, 2022 |
EX-10.5 16 tm229830d4ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] L |
|
| June 22, 2022 |
10-12B 1 tm229830d41012b.htm 10-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 98-0647155 (State or other jurisdiction of incorporation or organization) (I.R |
|
| June 22, 2022 |
EX-10.12.2 29 tm229830d4ex10-12d2.htm EXHIBIT 10.12.2 Exhibit 10.12.2 AMENDMENT NO. 2 TO CONSULTING AGREEMENT This Amendment No. 2 to Consulting Agreement (“Amendment No. 2”) is made as of last date of signature below (“Amendment No. 2 Effective Date”), by and between ProMIS Neurosciences, Inc. with a principal place of business being 1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2 (“Company”) a |
|
| June 22, 2022 |
EX-10.19 38 tm229830d4ex10-19.htm EXHIBIT 10.19 Exhibit 10.19 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] U.S. Persons only (Oct 21, 2019) PROMIS NEUROSCIENCES INC. SUBSCRIPTION AGREEMENT FOR U.S. PERSONS HAVE YOU COMPLETED THIS SUBSCRIPTION AGR |
|
| June 22, 2022 |
Exhibit 10.24 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [l], 2021. THE COMMON SHARES UNDERLYING THIS CERTIFICATE ARE LISTED ON THE TORONTO STOC |
|
| June 22, 2022 |
EX-10.3 10 tm229830d4ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***] UBC File: F20-03911 COLLABORATIVE |
|
| June 22, 2022 |
EX-10.3.2 12 tm229830d4ex10-3d2.htm EXHIBIT 10.3.2 Exhibit 10.3.2 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: |
|
| June 22, 2022 |
EX-10.33 52 tm229830d4ex10-33.htm EXHIBIT 10.33 Exhibit 10.33 Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [** |
|
| June 22, 2022 |
EX-10.39 59 tm229830d4ex10-39.htm EXHIBIT 10.39 Exhibit 10.39 AMORFIX LIFE SCIENCES LTD. DEFERRED SHARE UNIT PLAN FOR CANADIAN SENIOR OFFICERS PART 1 GENERAL PROVISIONS Purpose 1.1 The purpose of this Plan is to provide an alternative form of compensation to satisfy annual and special bonuses payable to Senior Officers. The form of compensation will enable Senior Officers to participate in any inc |
